Anesthetics are thought to be involved in
immunomodulation.
Avertin is one of the safest and most commonly used
intravenous anesthetics in rodent experiments; it is also widely used in
euthanasia of
inflammatory bowel disease (IBD) models. This study aimed to define the role and mechanism of action of
Avertin on murine
colitis. We assessed the effects of a single
Avertin injection on
colitis using the disease activity index (DAI), pathology,
enzyme-linked
immunosorbent assay (ELISA), multiplex-ELISA, flow cytometry, and routine blood examination in wild-type (WT) and
dextran sodium sulphate (DSS)-treated mice. Although
Avertin caused acute
cecitis in WT mice after 24 h and aggravated
inflammation in the medium term, it alleviated
inflammation in the late stage of DSS-induced
colitis according to the DAI.
Avertin upregulated MPO production and induced the accumulation of neutrophils and macrophages in intestinal mucosa of both WT and DSS-treated mice; the altered MPO might indicate a change in respiratory burst. However, it exhibited a more effective suppression of inflammatory factors secreted by macrophages as the
colitis progressed.
Avertin led to an increase in neutrophils and decrease in monocytes in both WT and DSS-treated mice blood. Our findings suggest that
Avertin aggravates
inflammation in the early and medium terms, but alleviates
inflammation in the late stage of
colitis by regulating neutrophils and macrophages.